| Autor: |
Victoria Mateos, Maria Richardson, Paul G. Dimopoulos, Meletios A. Palumbo, Antonio Anderson, Kenneth C. Shi, Hongliang and Elliott, Jennifer Dow, Edward van de Velde, Helgi Niculescu, Liviu San Miguel, Jesus F. |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| Popis: |
This analysis, using data from the bortezomib-melphalan-prednisone (VMP) arm of the Phase III VISTA study, investigated whether increased cumulative bortezomib dose could improve overall survival (OS) in transplant-ineligible patients with previously untreated multiple myeloma. Median cumulative bortezomib dose received by the 340 patients was 39 mg/m(2); this was selected as the cut-off for defining the dose groups to be compared for OS. Patient characteristics were well balanced between dose groups except for age. OS was significantly longer in the higher (39 mg/m(2)) versus lower ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
